# Pulse Biosciences, Inc (PLSE) Stock Analysis: Unveiling a 64% Potential Upside

- Link: https://www.directorstalkinterviews.com/pulse-biosciences-inc-plse-stock-analysis-unveiling-a-64-potential-upside/4121243891
- Published: 2026-03-10T11:38:21+00:00
- Author: Madison Wilson

Pulse Biosciences, Inc. (NASDAQ: PLSE) is a compelling player in the healthcare 
sector, specifically within the medical instruments and supplies industry. Based
in the United States, this innovative company is making waves with its pioneering
bioelectric medicine technologies, aiming to revolutionize treatments across various
medical fields.

With a market capitalization of $1.24 billion, Pulse Biosciences stands as a significant
entity in its sector. Its current stock price hovers at $18.255, reflecting a modest
daily change of 0.01%. However, the most striking aspect for investors is the potential
upside of 64.34%, as indicated by its average target price of $30.00 set by analysts.

Despite its promising technologies, Pulse Biosciences is currently not reporting
positive earnings, with a forward P/E ratio of -21.23 and an EPS of -1.08. The company’s
financial performance also shows a significant return on equity of -74.45% and a
negative free cash flow of approximately $29.5 million. These figures highlight 
the challenges ahead in achieving profitability and sustainable cash flow.

Nevertheless, the company’s strategic focus on its nPulse System and related technologies,
including the nPulse Vybrance Percutaneous Electrode system and the nPulse Cardiac
Surgical Clamp, positions it well for growth. These innovations cater to needs in
both dermatological and cardiac surgical treatments, potentially addressing significant
market demands.

Investors should note the absence of a dividend yield, as Pulse Biosciences reinvests
its resources into research and development to support future growth. The company’s
payout ratio sits at 0.00%, reflecting its focus on innovation over dividends.

Analyst sentiment towards Pulse Biosciences is optimistic, with two buy ratings 
and no hold or sell ratings. This bullish outlook is likely influenced by the stock’s
technical indicators, which show a 50-day moving average of $17.12 and a 200-day
moving average of $16.18, suggesting a generally upward trajectory. Meanwhile, the
RSI (14) of 42.11 indicates that the stock is not currently overbought, presenting
potential buying opportunities for investors.

Pulse Biosciences’ innovative approach and ambitious growth potential make it an
intriguing option for investors willing to embrace some risk in exchange for substantial
upside potential. The company’s dedication to advancing its cutting-edge bioelectric
medicine technologies could pave the way for significant breakthroughs, leading 
to future profitability and shareholder value. As always, investors should conduct
thorough due diligence and consider their risk tolerance before making investment
decisions.

Share on:
